Skip to content

Exosome therapy of Non-obstructive Azoospermia and Cryptospermia

A Novel Approach to Male Infertility Treatment Using Exosomes Derived from Adipose Tissue–Mesenchymal Stem Cells: Evaluation of Safety and Efficacy of Intratesticular Injection in Patients with Cryptozoospermia and Azoospermia

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251201068168N1
Enrollment
60
Registered
2025-12-02
Start date
2026-01-21
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Non-obstructive Azoospermia. Condition 2: Cryptozoospermia. Azoospermia

Interventions

Intervention 1: Intervention group 1: Men with non-obstructive azoospermia. Type of intervention: Intratesticular injection of Wharton's jelly MSC-derived exosomes. Dose: 2 intratesticular injections

Sponsors

Iranian academic center for education culture and research
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
25 Years to 45 Years

Inclusion criteria

Inclusion criteria: Age 25 to 45 years Proof of cryptozoospermia and non-obstructive azoospermia in at least 2 previous semen analyses (with an interval of 15 days) Diagnosis of cryptozoospermia and non-obstructive azoospermia (hormonal evaluation) BMI less than 35 Idiopathic NOA FSH more than 7.6 IU/ML Total testicular length less than 4.5 cm one year before diagnosis Testicular volume less than 12 cc Non-atrophic testicle (proven by ultrasound) Normal karyotype

Exclusion criteria

Exclusion criteria: Patients with NOA due to hypogonadotropic hypogonadism Receiving hormones and gonadotoxic drugs in the past 6 months History of stroke/heart attack in the past year Anemia and any other hematological disorder History of pelvic trauma Patients with NOA with LH less than 2IU/ml and FSH less than 1IU/ml Infectious diseases of the genital system History of testicular surgery Testicular biopsy and anatomical disorders of the genital system History of alcohol and drug use Thyroid disorders Immune system diseases Genetic abnormalities in the genital tract History of cancer and chemotherapy and radiotherapy Hepatitis B and C and AIDS Diabetic liver disorder Varicocele Hyperprolactinemia Spouse over 40 years old Patients with systemic medical problems Patients with chromosomal disorders Infertile spouse

Design outcomes

Primary

MeasureTime frame
Incidence and severity of inflammation and infection. Timepoint: Assessment at 24 hours, 72 hours, and one week after each injection. Method of measurement: Checking the amount of activated protein C and the erythrocyte sedimentation rate in a blood sample.;Incidence and severity of immune reaction. Timepoint: Assessment at 24 hours, 72 hours, and one week after each injection. Method of measurement: Checking the amount of immunoglobulin E and performing the complete blood count test.;Sperm retrival. Timepoint: Before the start of the study and 3 months and 6 months after the last injection. Method of measurement: Performing the sperm analysis test.

Secondary

MeasureTime frame
Serum testosterone level. Timepoint: Before intervention, 3 months, and 6 months after the last injection. Method of measurement: Quantitative measurement using Enzyme-Linked Immunosorbent Assay (ELISA) from peripheral blood samples.;Serum Luteinizing Hormone (LH) Level. Timepoint: Before intervention, 3 months, and 6 months after the last injection. Method of measurement: Quantitative measurement using Enzyme-Linked Immunosorbent Assay (ELISA) from peripheral blood samples.;Serum Follicle-Stimulating Hormone (FSH) Level. Timepoint: Before intervention, 3 months, and 6 months after the last injection. Method of measurement: Quantitative measurement using Enzyme-Linked Immunosorbent Assay (ELISA) from peripheral blood samples.;Sperm Parameters (Count, Motility, Morphology). Timepoint: Before intervention, 3 months, and 6 months after the last injection. Method of measurement: Semen analysis according to WHO Laboratory Manual standards, performed by two independent andrologists.;Fertilization Rate. Timepoint: 24 hours after Intracytoplasmic Sperm Injection (ICSI) procedure. Method of measurement: Percentage of fertilized oocytes (2PN) per injected oocytes under inverted microscopy.;Biochemical Pregnancy. Timepoint: 2–3 weeks after embryo transfer. Method of measurement: Detection of serum ß-hCG confirming biochemical pregnancy.;Clinical Pregnancy. Timepoint: 3–5 weeks after embryo transfer. Method of measurement: Confirmation by transvaginal ultrasound showing gestational sac and fetal heartbeat.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzar Sheikholeslami

Iranian academic center for education culture and research

azareslami10@gmail.com+98 25 3270 0155

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026